NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce the closing of its previously announced brokered private placement (the “Private Placement”). A total of 6,306,300 common shares of the Company (the “Shares”) were sold to investors resident in Peru and Chile at a price per Share of C$2.22 (approximatel ...

Core Points - FireFly Metals Ltd has successfully completed an equity raising totaling approximately A$139 million (C$127.3 million) before costs, enhancing its cash balance to A$236.9 million before transaction costs [1][32]. - The Canadian Offering, part of the equity raising, was underwritten by a syndicate led by BMO Capital Markets, with RBC Capital Markets and Canaccord Genuity Corp also participating [2][6]. - The underwriters exercised their full 15% over-allotment option, resulting in the issuance of 22,115,385 ordinary shares [3]. - A Share Purchase Plan (SPP) is being offered to eligible shareholders, allowing subscriptions of up to A$30,000 worth of shares at A$1.70 each, aiming to raise up to A$5 million [4][5]. - The SPP received applications significantly exceeding the target amount, leading to an early closure on December 19, 2025 [5]. Equity Raising Details - The equity raising included an institutional placement of A$85 million (C$77.8 million) at A$1.70 per share, completed on December 12, 2025 [7]. - A Canadian bought deal offering raised C$34.5 million (A$37.7 million) at C$1.56 per share, completed on December 17, 2025 [7]. - A charity flow-through placement raised approximately A$16.4 million (C$15 million) at about A$2.09 per share, completed on December 11, 2025 [7]. Mineral Resource Estimates - The Green Bay Copper-Gold Project hosts a total of 50.4 million tonnes of Measured and Indicated Mineral Resources at a grade of 1.7% for 863,000 tonnes of copper equivalent [13][28]. - The Inferred Mineral Resource for the Green Bay Project stands at 29.3 million tonnes at a grade of 1.9% for 566,000 tonnes of copper equivalent [28]. - The Pickle Crow Gold Project has an Inferred Mineral Resource of 11.9 million tonnes at 7.2 g/t for 2.8 million ounces of gold [14]. Government Support - The company acknowledges financial support from the Government of Newfoundland and Labrador through the Junior Exploration Assistance Program for various exploration activities [9].

Core Viewpoint - Tiziana Life Sciences has initiated a Phase 2 clinical trial for intranasal foralumab, targeting early Alzheimer's disease, marking a significant step in exploring immunomodulatory therapies for neuroinflammation [1][3][7]. Group 1: Clinical Trial Details - The Phase 2 trial is randomized and placebo-controlled, assessing the safety, tolerability, and potential efficacy of intranasal foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab [4]. - Primary endpoints of the trial include neuroinflammation measured by TSPO-PET imaging, cognitive function, and changes in amyloid and tau biomarkers, with interim data expected in 2026 [4]. Group 2: Scientific Rationale - TSPO-PET imaging data indicates persistent microglial activation in Alzheimer's patients, even after treatment with anti-amyloid therapies, highlighting the need for therapies that address residual neuroinflammation [2]. - Intranasal foralumab is designed to modulate immune responses and reduce activated microglia, potentially slowing disease progression in early Alzheimer's disease [2][3]. Group 3: Company Insights - Gabriele Cerrone, Chairman & Founder, emphasized the importance of this trial in exploring a novel approach to Alzheimer's treatment, building on previous data showing foralumab's ability to reduce microglial activation in multiple sclerosis patients [3]. - Ivor Elrifi, CEO, expressed enthusiasm for the rapid progress from enrollment to first patient dosing, reflecting the urgent need for new treatment strategies beyond amyloid clearance [3]. Group 4: About Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally, with previous studies showing positive outcomes in patients with non-active secondary progressive multiple sclerosis [5][6]. - It is the only fully human anti-CD3 monoclonal antibody currently in clinical development, representing a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [6]. Group 5: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, aiming to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [6][8].

Core Insights - Plug Power Inc. has successfully installed a 5MW GenEco electrolyzer system for Cleanergy Solutions Namibia's green hydrogen project, marking Africa's first fully integrated commercial green hydrogen facility [1][4] - The project aims to support hydrogen mobility in Namibia and neighboring markets, utilizing renewable energy sources [2][3] Company Overview - Plug Power is a leader in the hydrogen economy, providing a fully integrated ecosystem that includes production, storage, delivery, and power generation [5] - The company has deployed over 72,000 fuel cell systems and 285 fueling stations globally, making it the largest user of liquid hydrogen [6] Project Details - The Cleanergy Solutions Namibia project features a 5MW solar park and a 5.9 MWh battery energy storage system, enabling off-grid renewable hydrogen production [2] - The locally generated hydrogen will be used for hydrogen-powered trucks, port and rail equipment, and small ships at the Port of Walvis Bay [2][3] Market Positioning - The project positions Namibia as a potential hydrogen production hub for transportation and industrial decarbonization, with export capabilities [4] - Plug Power's involvement in this project aligns with the growing global investment in hydrogen, particularly in regions like Africa, the Middle East, and Australia [4]

Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found to be safe and effective, warranting a Phase 2 trial HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive results from the Emor ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Morien Resources Corp. (“Morien” or the “Company”) (TSX-V: MOX) is pleased to announce that it has closed its previously announced non-brokered Listed Issuer Financing Exemption offering (the “LIFE Offering”), raising gross proceeds of $1,600,000 through the issuance of 8,888,889 common shares (the “Common Shares”) of the Company at a price of $0.18 per sh ...

Core Viewpoint - Alaris Equity Partners Income Trust has successfully completed an offering of convertible unsecured senior debentures totaling $115 million, which will be used to repay existing debt and fund future investments [1][3]. Group 1: Offering Details - The offering consisted of $115 million in aggregate principal amount of debentures priced at $1,000 each, including a $15 million over-allotment option [1]. - The debentures will bear an interest rate of 6.25% per annum, with interest payments made semi-annually starting June 30, 2026 [2]. - The maturity date for the debentures is set for December 31, 2030, and they will begin trading on the Toronto Stock Exchange under the symbol "AD.DB.C" [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to partially repay outstanding indebtedness under Alaris' subsidiary's senior credit facility, which may be redrawn for future investments or general trust purposes [3]. Group 3: Company Overview - Alaris invests in a diversified group of private businesses primarily through structured equity, aiming to deliver stable and predictable returns to unitholders through cash distributions and capital appreciation [4].

Its Second University Launched Under Its NIL Strategic Initiative in the $36.4 Billion Global Licensed Sports Merchandise Market Austin, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- DBGI Corp. (Ticker: [NASDAQ:DBGI] a publicly traded company specializing in eCommerce and Fashion today announced its first activation AVO clothing activation at the University of Mississippi for the home playoff game featuring the Tulane Green Wave vs. The Ole Miss Rebels this Saturday, December 20th in Oxford, MS. The first Ole M ...

Geneva, Switzerland, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SEALSQ Owns 28.3% Stake in WECAN Via Strategic Investments Focused on Quantum Technology Integration SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that WeCanGroup SA (“WECAN”), a blockchain-based solutions entity in which SEALSQ owns a 28.3% minority stake, was awarded a grant from Hedera. The receipt o ...

Summary: SoundThinking opens a new in-office Alert Review Center in downtown Orlando, FL, creating a centralized operational hub and the opportunity for nearly 30 public-safety jobs in the region. FREMONT, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, today announced the opening of its new Alert Review Center (ARC) in downtown Orlando. The office will serve as the permanent home for the company’s SafePointe® alert review operations, ...